These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 31565009)

  • 1. Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease.
    Cheloff AZ; Al-Samkari H
    J Blood Med; 2019; 10():313-321. PubMed ID: 31565009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avatrombopag for the Treatment of Immune Thrombocytopenia and Periprocedural Thrombocytopenia Associated With Chronic Liver Disease.
    Tran TB; Downing L; Elmes JB; Arnall JR; Moore DC
    J Pharm Pract; 2024 Feb; 37(1):184-189. PubMed ID: 36113085
    [No Abstract]   [Full Text] [Related]  

  • 3. An evaluation of avatrombopag for the treatment of thrombocytopenia.
    Virk ZM; Kuter DJ; Al-Samkari H
    Expert Opin Pharmacother; 2021 Feb; 22(3):273-280. PubMed ID: 33095074
    [No Abstract]   [Full Text] [Related]  

  • 4. Avatrombopag: A Review in Thrombocytopenia.
    Markham A
    Drugs; 2021 Nov; 81(16):1905-1913. PubMed ID: 34709601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease.
    Xu H; Cai R
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):859-865. PubMed ID: 31352834
    [No Abstract]   [Full Text] [Related]  

  • 6. Avatrombopag maleate for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease.
    Al-Samkari H
    Drugs Today (Barc); 2018 Nov; 54(11):647-655. PubMed ID: 30539164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avatrombopag for the treatment of immune thrombocytopenia.
    Długosz-Danecka M; Zdziarska J; Jurczak W
    Expert Rev Clin Immunol; 2019 Apr; 15(4):327-339. PubMed ID: 30799645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.
    Kuter DJ
    Blood Rev; 2022 May; 53():100909. PubMed ID: 34815110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.
    Jurczak W; Chojnowski K; Mayer J; Krawczyk K; Jamieson BD; Tian W; Allen LF
    Br J Haematol; 2018 Nov; 183(3):479-490. PubMed ID: 30191972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure.
    Terrault NA; Hassanein T; Howell CD; Joshi S; Lake J; Sher L; Vargas H; McIntosh J; Tang S; Jenkins TM
    J Hepatol; 2014 Dec; 61(6):1253-9. PubMed ID: 25048952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
    Terrault N; Chen YC; Izumi N; Kayali Z; Mitrut P; Tak WY; Allen LF; Hassanein T
    Gastroenterology; 2018 Sep; 155(3):705-718. PubMed ID: 29778606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives.
    Tsykunova G; Ghanima W
    Ther Clin Risk Manag; 2022; 18():273-286. PubMed ID: 35386180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension.
    Al-Samkari H; Nagalla S
    Platelets; 2022 Feb; 33(2):257-264. PubMed ID: 33586606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avatrombopag for adults with early versus chronic immune thrombocytopenia.
    Virk ZM; Leaf RK; Kuter DJ; Goodarzi K; Connell NT; Connors JM; Al-Samkari H
    Am J Hematol; 2024 Feb; 99(2):155-162. PubMed ID: 38063420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies.
    Kuter DJ; Allen LF
    Br J Haematol; 2018 Nov; 183(3):466-478. PubMed ID: 30203841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avatrombopag: First Global Approval.
    Shirley M
    Drugs; 2018 Jul; 78(11):1163-1168. PubMed ID: 29995177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eltrombopag: a novel oral thrombopoietin receptor agonist.
    Corman SL; Mohammad RA
    Ann Pharmacother; 2010 Jun; 44(6):1072-9. PubMed ID: 20460556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review.
    Agarwal N; Mangla A
    Ther Adv Hematol; 2021; 12():20406207211001139. PubMed ID: 33796239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 study of avatrombopag in Japanese patients with chronic liver disease and thrombocytopenia.
    Eguchi Y; Takahashi H; Mappa S; Santagostino E
    Hepatol Res; 2022 Apr; 52(4):371-380. PubMed ID: 35134259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia.
    Al-Samkari H; Kuter DJ
    Ther Adv Hematol; 2019; 10():2040620719841735. PubMed ID: 31007886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.